ArticleDermatology and therapy2024

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).

Melinda Gooderham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.